Category Archives: Press Releases

SEC Delivers Report to Congress with Recommendations from 40th Annual Small Business Forum

Posted on by
Reply

Washington D.C., Sept 27, 2021 — Today the Office of the Advocate for Small Business Capital Formation delivered a report to Congress on the Securities and Exchange Commission’s 40th Annual Small Business Forum. The 2021 Forum took place virtually on May 24–27, 2021, with each session featuring panelists with in-depth knowledge of the issues facing small businesses across the country, spotlighting the following topics:

  • Monday, May 24: Finding Your First Dollars: Navigating Your Way to Raise Early Rounds
  • Tuesday, May 25: Doing Your Diligence: How Savvy Early-Stage Investors Build Diversified Portfolios
  • Wednesday, May 26:  Diversifying Capital Allocators: Tools for Emerging and Smaller Funds and Their Managers
  • Thursday, May 27:  Small Cap Insights: Perspectives on Smaller Public Companies

The report provides a summary of the Forum proceedings, including the recommendations developed by participants for changes needed to the capital raising framework and the Commission’s responses to the recommendations. Continue reading →

BridgeBio Pharma and LianBio Announce First Patient Treated in Phase 2a Trial of Infigratinib

Posted on by
Reply

August 25, 2021– Palo Alto, California & Shanghai & Princeton, New Jersey (Business Wire) — LianBio, a biotechnology company dedicated to bringing paradigm-shifting medicines to patients in China and other major Asian markets, and BridgeBio Pharma, Inc. (Nasdaq: BBIO) today announced the first patient has been treated in a Phase 2a clinical trial of infigratinib in patients with locally advanced or metastatic gastric cancer or gastroesophageal junction adenocarcinoma with fibroblast growth factor receptor-2 (FGFR2) gene amplification and other advanced solid tumors with FGFR genomic alterations.

“We believe that infigratinib could have a meaningful impact for people living with gastric cancer as well as many other cancers with FGFR alterations, and are pleased LianBio is initiating this clinical trial in China where more therapeutic options are needed to match the growing diagnosis rate.”

“Infigratinib is a potent and selective FGFR inhibitor that has demonstrated compelling clinical activity across multiple tumor types with FGFR alterations,” said Yizhe Wang, Ph.D., chief executive officer of LianBio. “Given the disproportionately high prevalence rate of gastric cancer in China, LianBio is pursuing a region-specific development strategy focused on this area of great unmet need. This study marks LianBio’s first trial initiation and demonstrates our continued progress in delivering potentially transformational medicines to patients in Asia.” Continue reading →

‘Building the New Economy’ by MIT Sloan School

Posted on by
Reply

‘Building the New Economy’: MIT Sloan School researchers map out a blueprint to help individuals, infrastructure, and institutions withstand crises, from wars to pandemics

New digital technologies can help build resilient systems and empower communities

News provided by MIT Sloan School of Management, May 22, 2020, 07:30 ET

CAMBRIDGE, MA, May 22, 2020 — How can we make our financial system less fragile and more transparent? How can we make our healthcare infrastructure less reactive and more agile? And what can we do to create more robust civic institutions that work for all of us—not just those at the top?

A new book from researchers at the MIT Sloan School of Management provides answers and insights to those pressing questions. The book, Building the New Economy, is edited by Professor Alex “Sandy” Pentland, leader within the Sloan Initiative for Digital Economy and founder of the MIT-wide Connection Science program, Alexander Lipton, former Managing Director of Quantitative Solutions at Bank of America and Connection Science Fellow at MIT, and Thomas Hardjono, CTO of Connection Science and Technical Director of the MIT Trust-Data Consortium.

“With each new crisis, be it war, pandemic, natural disaster, or even the invention of a major technology, there has been a need to reinvent the relationships between individuals, businesses, and governments. The COVID-19 health emergency and ensuing economic turmoil, joined with the tsunami of data and AI technologies—is such a crisis,” says Prof. Pentland. Continue reading →

Americaweb.org